

**MHACO** 

83.2%

70.7%

55.3%

15.2%

## MHACO Quality Heat Map (January 2024) Report Data 01/01/2023 - 12/31/2023 Depression Colorectal DM HbA1c **DM Kidney** HPV Pt. Exp -DM HbA1c **DM Statin** HTN BP **DM Eye Screening &** Cancer **Disparities** Health Vaccination Would Measure > 9% Exam Therapy Control Follow-Up **Evaluation** Screening Gap Series Recommend 84.0% 76.2% 17.0% 83.6% Target 68.0% 9.0% 55.0% *52.0% 75.2%* 88.1% Franklin 82.3% 61.9% 45.8% 16.2% 12.4% 61.9% 69.2% 50.5% 78.4% 85.3% Lincoln 85.7% 74.0% 65.3% 17.4% 4.8% 65.0% 71.3% 47.4% 72.0% 87.7% Memorial 93.8% 76.2% 71.4% 13.4% 19.2% 59.9% 73.7% 56.5% 75.3% 87.9% **Mid Coast** 76.6% 73.2% 60.1% 15.4% 58.9% 69.6% 33.8% 89.8% 12.8% 67.5% MMC/MMP (Empl) 84.6% 71.3% 53.4% 64.3% 74.8% 50.9% 72.0% 15.3% 6.5% 88.1% Pen Bay 84.4% 71.4% 64.4% 14.4% 10.1% 68.4% 72.8% 42.6% 74.9% 84.6% **Southern Maine** 79.4% 65.6% 48.9% 14.9% 11.8% 57.5% 74.2% 48.2% 70.8% 85.0% St Mary's N/A 76.0% 46.7% 15.9% 15.4% 60.3% 82.3% 26.7% 80.8% 82.9% Waldo 92.7% 67.9% 73.1% 65.8% 11.6% 10.8% 75.7% 47.0% 75.9% 87.2% 82.7% 72.8% 76.1% 66.4% 10.5% 54.8% 75.4% 85.7% Western 15.7% 69.7%

9.1%

62.5%

74.3%

47.6%

73.3%

86.8%



| MHACO Quality Heat Map Measure Descriptions |   |
|---|---|
|   | <b>Numerator</b> : Patients aged 12 years and older screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age-appropriate standardized tool AND if positive, a follow-up plan is documented on the date of the eligible encounter or up to two days after the qualifying encounter.   |
| Depression Screening & Follow-Up            | <b>Denominator</b> : Number of patients ages 12 and older at the beginning of the measurement period, with an office visit in the last 12 months.   |
|   | <b>Exclusions:</b> Patients who have been diagnosed with bipolar disorder, refuse, or there is a documented medical reason for not screening the patient for depression (e.g., cognitive, functional, or motivational limitations that may impact accuracy of results; patient is in an urgent or emergent situation where time is of the essence and to delay treatment would jeopardize the patient's health status).   |
| Colorectal Cancer Screening                 | <b>Numerator</b> : Number of patients with one or more screenings documented for colorectal cancer: colonoscopy in the last 10 years; flexible sigmoidoscopy in the last 5 years; computed tomography colonography in the last 5 years; multi-target stool DNA test/Cologuard in the last 3 years; or a fecal immunochemical test (FIT) or fecal occult blood test (FOBT) in the past 12 months   |
|   | Denominator: Number of patients ages 45-75 at the beginning of the measurement period, with an office visit in the last 12 months.  |
|   | Exclusions: A diagnosis or past history of total colectomy or colorectal cancer.  |
| DM - Eye Exam                               | <b>Numerator</b> : Number of patients in the denominator with documentation of a retinal or dilated eye exam in the last 24 months or last 12 months for patients with retinopathy.   |
|   | <b>Denominator:</b> Number of patients with diabetes (type 1 or type 2), ages 18-75 at the beginning of the measurement period diagnosed and having an office visit during the measurement period.  |
| DM - HbA1c > 9                              | <b>Numerator</b> : Number of patients in the denominator with either: the most recent HbA1c (within the last 12 months) that is > 9% OR no HbA1c test was completed.  |
|   | <b>Denominator</b> : Number of patients with diabetes (type 1 or type 2), ages 18-75 at the beginning of the measurement period diagnosed and having an office visit during the measurement period.   |
|   | <b>Exclusions:</b> Exclude patients 66 and older by the end of the measurement period with an indication of frailty for any part of the measurement period who also meet any of the following advanced illness criteria: advanced illness with two outpatient encounters during the measurement period or the year prior- OR advanced illness with one inpatient encounter during the measurement period or the year prior- OR taking dementia medications during the measurement period or the year prior. |
| DM HbA1c Disparities Gap                    | <b>Disparities Gap:</b> The delta between the rate of control for patients with commercial insurance coverage compared to the rate of control for an aggregate rate of patients with MaineCare and no insurance coverage.   |



| MHACO Quality Heat Map Measure Descriptions |   |
|---|---|
|   | Numerator from HbA1c > 9% measure: Number of patients in the denominator whose most recent HbA1c (within the last 12 months) is > 9% or no HbA1c test was completed.  |
|   | <b>Denominator from HbA1c &gt; 9% measure:</b> Number of patients with diabetes (type 1 or type 2), ages 18-75 at the beginning of the measurement period diagnosed and having an office visit during the measurement period.   |
| DM - Kidney Health Evaluation               | <b>Numerator</b> : Number of patients who received an annual kidney health evaluation, including both estimated glomerular filtration rate (eGFR) and urine microalbumin/creatinine ratio (uACR).   |
|   | <b>Denominator:</b> Number of patients with Diabetes (Type 1 or Type 2), ages 18-75 at the beginning of the measurement period diagnosed, and having an office visit during the measurement period.   |
|   | Exclusions: End-Stage Renal Disease, frailty and advanced illness.  |
| DM - Statin Therapy                         | Numerator: Patients in the denominator who were seen in the last year with an active statin medication of any intensity on their medication list.   |
|   | <b>Denominator</b> : Number of patients with diabetes (type 1 or type 2), ages 40-75 at the beginning of the measurement period diagnosed and having an office visit during the measurement period.   |
|   | Exclusions: Clinical atherosclerotic cardiovascular disease (ASCVD)   |
| HPV Vaccination Series                      | Numerator: Number of patients in the denominator who received 2 doses of HPV vaccine by their 13th birthday.  |
|   | <b>Denominator:</b> Total number of patients 13 years of age as of the end of the measurement period.   |
| HTN BP Control                              | Numerator: Number of patients in the denominator whose most recent and lowest of BP reading of the day in the last 12 months is < 140/90.   |
|   | <b>Denominator</b> : Number of patients with essential (primary) hypertension, ages 18-85 at the beginning of the measurement period diagnosed, with an office visit in the last 12 months.   |
|   | Exclusions: End-Stage Renal Disease, pregnancy.   |
| Patient Experience – Would<br>Recommend     | <b>Numerator:</b> Net promoter score* for email/phone survey question, "How likely would you be to recommend this office to your family and friends?" for the National Patient Experience Survey question from NRC (rolling 3 months).  *Net promoter score: % of patients with a 9-10 rating minus % of patients with a 0-6 rating |
|   | <b>Denominator:</b> Number of patients surveyed by the National Patient Experience Survey question within the past rolling 3 months.  |